Synthesis of five nevirapine metabolites
- 11 March 2000
- journal article
- research article
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 37 (2), 229-239
- https://doi.org/10.1002/jhet.5570370203
Abstract
Nevirapine (1) is a non‐nucleoside reverse transcriptase inhibitor marketed for HIV treatment by Boehringer Ingelheim as Viramune® since 1996. In vitro studies of nevirapine biotransformation using human liver microsomes demonstrated the formation of five major metabolites. This paper describes the syntheses of these metabolites.This publication has 7 references indexed in Scilit:
- Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 7. 8-Arylethyldipyridodiazepinones as Potent Broad-Spectrum Inhibitors of Wild-Type and Mutant EnzymesJournal of Medicinal Chemistry, 1998
- Drug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical useExpert Opinion on Investigational Drugs, 1996
- Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase EnzymesJournal of Medicinal Chemistry, 1995
- Sommelet-hauser rearrangement of an ammonium ylide derived from the HIV-1 reverse transcriptase inhibitor nevirapineJournal of Heterocyclic Chemistry, 1995
- Synthesis of nevirapine and its major metaboliteJournal of Heterocyclic Chemistry, 1995
- The synthesis of 11-cyclopropyl-5,11-dihydro-4-(hydroxymethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, a putative metabolite of the HIV-1 reverse transcriptase inhibitor nevirapineThe Journal of Organic Chemistry, 1992
- Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinonesJournal of Medicinal Chemistry, 1991